[1] |
Yoshida N, Omoto Y, Inoue A, et al.Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes[J].Cancer Sci, 2004, 95(6): 496-502.
|
[2] |
Parkin DM, Bray F, Ferlay J, et al.Global cancer statistics, 2002[J].CA Cancer J Clin, 2005, 55(2): 74-108.
|
[3] |
Paik S, Kim C, Wolmark N.HER2 status and benefit from adjuvant trastuzumab in breast cancer[J].N Engl J Med,2008, 358: 1409-1411.
|
[4] |
Hanna W, Kahn HJ, Trudeau M.Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside[J].Mod Pathol, 1999, 12(8): 827-834.
|
[5] |
Slodkowska J, Filas V, Buszkiewicz E, et al.Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio)[J].Folia Histochem Cytobiol, 2010,48(1): 19-25.
|
[6] |
Jiang HY, Zhang SQ, Zhao T.A new method to make nuclei or cell microarrays[J].Diagn Mol Pathol, 2006, 15(2): 109-114.
|
[7] |
Jiang HY, Zhang XF, Liu L, et al.A novel tissue array technique for high-throughput tissue microarray analysis:microarray groups[J].In Vitro Cell Dev Biol Anim, 2007, 43(3/4): 109-112.
|
[8] |
Mass RD,Press MF,Anderson S,et al.Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.Clin Breast Cancer,2005,6(3):240-246.
|
[9] |
Hicks DG, Tubbs RR.Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines[J].Hum Pathol, 2005, 36(3): 250-261.
|
[10] |
Dean Colomb W, Esteva FJ.Her2-positive breast cancer: herceptin and beyond[J].Eur J Cancer, 2008, 44(18):2806-2812.
|
[11] |
Park S, Jiang Z, Mortenson ED, et al.The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity[J].Cancer Cell, 2010, 18(2): 160-170.
|
[12] |
O'Malley FP, Thomson T, Julian J, et al.HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab[J].Arch Pathol Lab Med, 2008, 132(1): 61-65.
|
[13] |
Risio M, Casorzo L, Redana S, et al.HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment[J].Oncol Rep,2005,13(2): 305-309.
|